In their phase I/II trial, this group showed clinical responses in the treatment of patients with epidermal growth factor receptor (EGFR or HER1)‐expressing head and neck squamous cell carcinoma using a combination of s.c. administered IL‐12 and the anti‐EGFR monoclonal antibody cetuximab. Here, EGFR is linked to head and neck squamous cell carcinoma.